Bruker reports Q3 EPS 45c, consensus 33c

Reports Q3 revenue $860.5M, consensus $847.04M. Frank Laukien, Bruker’s (BRKR) president and CEO, commented: “In the third quarter, we were encouraged by our mid-single digit percentage organic bookings growth year-over-year, with a Scientific Instruments segment book-to-bill ratio greater than 1.0. For the first time this year, we saw strength in bookings in the academic/government market segment, as well as improving biopharma and applied markets orders. Notably, our innovative spatial biology, proteomics and multiomics solutions launched at AGBT and ASMS are being well received by our biopharma and academic customers and enhance our leadership in enabling tools for drug discovery and disease biology research in the post-genomic era.”